Drug Search Results
More Filters [+]

Selitrectinib

Alternative Names: selitrectinib, loxo-195, loxo195, loxo 195
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

For Solid Tumors Harboring NTRK Fusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03215511)

Mechanisms of Action: TRK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Selitrectinib

Countries in Clinic: Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Singapore, Spain, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2017-004246-20

P1

Completed

Oncology Unspecified

2023-06-21

LOXO-EXT-17005

P1

Completed

Oncology Solid Tumor Unspecified

2022-04-11

Recent News Events